Prof. Mats Jerkeman, MD, PhD

Lund University, Sweden

Mats Jerkeman is Professor in Clinical Oncology at Lund University, Sweden. Prof. Jerkeman is also Chairman of the Nordic Lymphoma Group and the National Guidelines for Lymphoma, Sweden. His research focuses on improving the quality of life and survival of patients with malignant lymphomas. He completed his doctoral training at Lund University, Sweden.

Prof. Jerkeman is the Coordinator of several ongoing clinical trials in diffuse large B-cell lymphoma and mantle cell lymphoma, and has also served as coordinator of the Swedish Lymphoma Register for many years. He is an Editor of the European Society of Medical Oncology Lymphoma Guidelines.He has over 140 publications in peer-reviewed journals.

Dr. Toby Eyre, MD

Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom

Dr. Toby Eyre is a consultant hematologist at Oxford University Hospitals NHS Foundation Trust specialising in the management of lymphoid malignancies. He is considered a national expert in the management of patients with lymphoma and patients with chronic lymphocytic leukemia (CLL). 

Dr. Eyre completed his hematology training in the Oxford Deanery between 2010 and 2017. He is an investigator on a number of national UK lymphoma and CLL trials and has published over 100 peer-review articles on areas of lymphoma and CLL and has presented regularly at national and international conferences.  

Dr. Eyre is a core member of the low-grade lymphoma and elderly high-grade lymphoma NCRI clinical studies group and a member of the BSCH guideline writing groups for various lymphoma subtypes. He also has a strong interest in teaching and training and has completed a post-graduate Diploma in Medical Education. 

Prof. Dr. Marion Subklewe, MD, PhD

LMU Gene Center, Munich, Germany

Marion Subklewe is Head of the Laboratory for Translational Cancer Immunotherapy at the Gene Center, Munich and Professor of Internal Medicine at Ludwig Maximilian University of Munich, Germany. She studied medicine at University Hospital Tübingen and completed her postdoctoral fellowship at Rockefeller University in New York.

Prof. Subklewe is current Head of the Immunotherapy Program in Hematology and the CAR T Program at University Hospital Munich, Founder and Speaker of the national “Harmonize MRD Flow” Consortium and member of the ELN Working group on MRD. She is also active in clinical research and has been Principal Investigator in 3 I-IT trials in AML and ALL, as well as in over 30 oligo- and multicentric Phase I trials in leukemia and lymphoma. In recognition of her work, Prof. Subklewe has received numerous honours and awards including the EHA Educational Presentation and ASH Abstract Achievement Awards.

Prof. Steven Le Gouill, MD, PhD

Institut Curie Hospitals Group, Paris, France

Prof. Steven Le Gouill is Director of the Hospital Group at Institut Curie. He was Chair of the Scientific Advisory Board of LYSA (network for clinical lymphoma research) and National Coordinator of the French registry of CAR-T cells
(DESCAR-T). Since 1999, he has been a member of the research team, “Regulation of BCL-2 and p53 networks in multiple myeloma and Mantle-cell lymphoma”.